Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Song, Xuejiao ^a   Gao, Tiantao ^a   Wang, Ningyu ^a   Feng, Qiang ^a,c   You, Xinyu ^b   Ye, Tinghong ^a   Lei, Qian ^a   Zhu, Yongxia ^a   Xiong, Menghua ^a   Xia, Yong ^a   Yang, Fangfang ^a   Shi, Yaojie ^a   Wei, Yuquan ^a   Zhang, Lidan ^a   Yu, Luoting ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c CHENGDU NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; HISTONE; MOLECULAR LIBRARY; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONE DERIVATIVE; QUINOLONE DERIVATIVE; TRANSCRIPTION FACTOR EZH2; ZLD1039;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; BREAST TUMOR; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; HUMAN; INTRACELLULAR SPACE; METABOLISM; METASTASIS; METHYLATION; MOLECULAR LIBRARY; NUDE MOUSE; PATHOLOGY; PHARMACOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; FEMALE; HISTONES; HUMANS; INTRACELLULAR SPACE; METHYLATION; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONES; QUINOLONES; SMALL MOLECULE LIBRARIES; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958568425     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20864     Document Type: Article

References (42)

1. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
2. Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480-488 (2013).
3. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011).
4. Kubicek, S. et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25, 473-481 (2007).
5. Liu, F. et al. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. J. Med. Chem. 56, 2110-2124 (2013).
6. Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B. & Cavalli, G. Genome regulation by polycomb and trithorax proteins. Cell 128, 735-745 (2007).
7. Sauvageau, M. & Sauvageau, G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7, 299-313 (2010).
8. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 100, 11606-11611 (2003).
9. Bödör, C. et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 25, 726-729 (2011).
10. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
11. Lin, N. U. et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118, 5463-5472 (2012).
12. Gluz, O. et al. Triple-negative breast cancer-current status and future directions. Ann. Oncol. 20, 1913-1927 (2009).
13. Gong, Y. et al. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117, 5476-5484 (2011).
14. Collett, K. et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 12, 1168-1174 (2006).
15. Fujii, S. et al. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 30, 4118-4128 (2011).
16. Bracken, A. P. et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323-5335 (2003).
17. Shi, B. et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol. Cell Biol. 27, 5105-5119 (2007).
18. Gonzalez, M. E. et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28, 843-853 (2009).
19. Liu, T. P., Lo, H. L., Wei, L. S., Hsiao, H. H. & Yang, P. M. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells. Anticancer Drugs 26, 139-147 (2015).
20. Gonzalez, M. E. et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc. Natl. Acad. Sci. USA 111, 3098-3103 (2014).
21. Verma, S. K. et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med. Chem. Lett. 3, 1091-1096 (2012).
22. Zhang, L. D. et al. Design, synthesis and biological evaluation of novel 1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinolins as potential EZH2 inhibitors. RSC Adv. 5, 25967-25978 (2015).
23. Konze, K. D. et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324-1334 (2013).
24. Knutson, S. K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896 (2012).
25. Qi, W. et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. USA 109, 21360-21365 (2012).
26. Knutson, S. K. et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 110, 7922-7927 (2013).
27. Richon, V. M. et al. Chemogenetic analysis of human protein methyltransferases. Chem. Biol. Drug Des. 78, 199-210 (2011).
28. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl. J. Med. 364, 2507-2516 (2011).
29. Jiao, L. & Liu, X. Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Science 350, 6258 (2015).
30. Ren, G. et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 72, 3091-3104 (2012).
31. Wu, Y. et al. Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. Int. J. Oncol. 46, 2586-2594 (2015).
32. Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48 (2012).
33. Ryan, R. J. & Bernstein, B. E. Genetic events that shape the cancer epigenome. Science 336, 1513-1514 (2012).
34. Chase, A. & Cross, N. C. Aberrations of EZH2 in cancer. Clin. Cancer Res. 17, 2613-2618 (2011).
35. Tsuruo, T. et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 94, 15-21 (2003).
36. Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348 (2001).
37. Zhou, X. et al. Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC. Oncotarget 6, 33720-33732 (2015).
38. Fujii, S., Ito, K., Ito, Y. & Ochiai, A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J. Biol. Chem. 283, 17324-17332 (2008).
39. Yang, X. et al. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 4, e5011 (2009).
40. Cao, Q. et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27, 7274-7284 (2008).
41. Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011).
42. Wang, Y. S. et al. Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice. Clin. Cancer Res. 15, 6901-6911 (2009).